Erratum: Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial (The Lancet (2015) 386(9998) (1049–1056) (S014067361560294X) (10.1016/S0140-6736(15)60294-X));Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: A phase 3 randomised trial

The Lancet

Volumn 386, Issue 9998, 2015, Pages 1049-1056

  Pless, Miklos ^a   Stupp, Roger ^b,c   Ris, Hans Beat ^b   Stahel, Rolf A ^c   Weder, Walter ^c   Thierstein, Sandra ^d   Gerard, Marie Aline ^d   Xyrafas, Alexandros ^d   Früh, Martin ^e   Cathomas, Richard ^f   Zippelius, Alfred ^g   Roth, Arnaud ^h   Bijelovic, Milorad ⁱ   Ochsenbein, Adrian ^j   Meier, Urs R ^a   Mamot, Christoph ^k   Rauch, Daniel ^l   Gautschi, Oliver ^m   Betticher, Daniel C ⁿ   Mirimanoff, René Olivier ^b   Peters, Solange ^b   more..

^a CANTONAL HOSPITAL WINTERTHUR   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d SWISS GROUP FOR CLINICAL CANCER RESEARCH SAKK   (Switzerland)

^e CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^f KANTONSSPITAL GRAUBÜNDEN   (Switzerland)

^g UNIVERSITY HOSPITAL BASEL   (Switzerland)

^h GENEVA UNIVERSITY HOSPITALS   (Switzerland)

ⁱ The Institute for Pulmonary Diseases of Vojvodina   (Serbia)

^j UNIVERSITY OF BERN   (Switzerland)

^k CANTONAL HOSPITAL AARAU   (Switzerland)

^l Regional Hospital   (Switzerland)

^m LUZERNER KANTONSSPITAL   (Switzerland)

ⁿ Hopital Cantonal de Fribourg   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; ANTINEOPLASTIC AGENT;

ADJUVANT CHEMORADIOTHERAPY; ADJUVANT THERAPY; ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER FATIGUE; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SIZE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED ANEMIA; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CHRONOTHERAPY; CONSTIPATION; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COUGHING; DIARRHEA; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG SUBSTITUTION; DYSPHAGIA; DYSPNEA; EDEMA; EVENT FREE SURVIVAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; GERMANY; HUMAN; HYPERSENSITIVITY; INDUCTION CHEMOTHERAPY; INFECTION COMPLICATION; INTENTION TO TREAT ANALYSIS; INTERVENTION STUDY; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; NEUTROPENIA; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION INDUCED EMESIS; RADIATION SICKNESS; RANDOMIZED CONTROLLED TRIAL; SERBIA; SKIN TOXICITY; STOMATITIS; SWITZERLAND; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; WEIGHT REDUCTION; ADVERSE EFFECTS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; LUNG NEOPLASMS; LUNG RESECTION; LYMPH NODE METASTASIS; MIDDLE AGED; PATHOLOGY; PROCEDURES; SECONDARY; SURVIVAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY, ADJUVANT; FEMALE; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; PNEUMONECTOMY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84941600372     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(15)00144-0     Document Type: Erratum

References (23)

1. P Goldstraw, J Crowley, K Chansky et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours J Thorac Oncol 2 2007 706 714
2. N O'Rourke, IFM Roque, N Farre Bernado, F Macbeth Concurrent chemoradiotherapy in non-small cell lung cancer Cochrane Database Syst Rev 6 2010 CD002140
3. A Auperin, C Le Pechoux, E Rolland et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer J Clin Oncol 28 2010 2181 2190
4. R Arriagada, A Auperin, S Burdett for the NSCLC Meta-analyses Collaborative Group Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data Lancet 375 2010 1267 1277
5. NSCLC Meta-analysis Collaborative Group Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data Lancet 383 2014 1561 1571
6. DC Betticher, SF Hsu Schmitz, M Totsch et al. Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial J Clin Oncol 21 2003 1752 1759
7. DC Betticher, SF Hsu Schmitz, M Totsch et al. Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study Br J Cancer 94 2006 1099 1106
8. KS Albain, VW Rusch, JJ Crowley et al. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805 J Clin Oncol 13 1995 1880 1892
9. R Stupp, M Mayer, R Kann et al. Neoadjuvant chemotherapy and radiotherapy followed by surgery in selected patients with stage IIIB non-small-cell lung cancer: a multicentre phase II trial Lancet Oncol 10 2009 785 793
10. G Stamatis, W Eberhardt, G Stuben, S Bildat, O Dahler, L Hillejan Preoperative chemoradiotherapy and surgery for selected non-small cell lung cancer IIIB subgroups: long-term results Ann Thorac Surg 68 1999 1144 1149
11. International Commission on Radiation Units and Measurements ICRU report 50: prescribing, recording and reporting photon beam therapy 1993 ICRU Publications Bethesda, MD
12. N Martini Mediastinal lymph node dissection for lung cancer. The Memorial experience Chest Surg Clin N Am 5 1995 189 203
13. J Fleck, J Camargo, D Godoy Chemoradiation therapy versus chemotherapy alone as a neoadjuvant treatment for stage III non-small cell lung cancer. Preliminary report of a phase III prospective randomized trial Proc Am Soc Clin Oncol 12 1993 1108a
14. JY Douillard, R Rosell, M De Lena, M Riggi, P Hurteloup, MA Mahe Impact of postoperative radiation therapy on survival in patients with complete resection and stage I, II, or IIIA non-small-cell lung cancer treated with adjuvant chemotherapy: the adjuvant Navelbine International Trialist Association (ANITA) Randomized Trial Int J Radiat Oncol Biol Phys 72 2008 695 701
15. PC O'Brien, TR Fleming A multiple testing procedure for clinical trials Biometrics 35 1979 549 556
16. KS Albain, RS Swann, VW Rusch et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial Lancet 374 2009 379 386
17. S Bentzen, M Joiner The linear quadratic approach in clinical practice M Joiner A van der Kogel Basic clinical radiology 4th edn. 2009 Taylor & Francis Boca Raton, FL
18. N Katakami, H Tada, T Mitsudomi et al. A phase 3 study of induction treatment with concurrent chemoradiotherapy versus chemotherapy before surgery in patients with pathologically confirmed N2 stage IIIA nonsmall cell lung cancer (WJTOG9903) Cancer 118 2012 6126 6135
19. N Girard, F Mornex, JY Douillard et al. Is neoadjuvant chemoradiotherapy a feasible strategy for stage IIIA-N2 non-small cell lung cancer? Mature results of the randomized IFCT-0101 phase II trial Lung Cancer 69 2010 86 93
20. M Thomas, C Rube, P Hoffknecht et al. Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non-small-cell lung cancer Lancet Oncol 9 2008 636 648
21. JP van Meerbeeck, GW Kramer, PE Van Schil et al. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer J Natl Cancer Inst 99 2007 442 450
22. W Eberhardt, T Gauler, C Pöttgen et al. Phase III study of surgery (S) versus definitive concurrent chemoradiotherapy boost (def ccCRTx-BOx) in patients (pts) with operable (OP+) stage IIIA(N2)/selected IIIb (sel IIIB) non-small cell lung cancer (NSCLC) following induction (IND) chemotherapy (CTx) and concurrent CRTx (ESPATUE) J Clin Oncol 32 suppl 2014 abstr 7510.
23. K Higgins, JP Chino, LB Marks et al. Preoperative chemotherapy versus preoperative chemoradiotherapy for stage III (N2) non-small-cell lung cancer Int J Radiat Oncol Biol Phys 75 2009 1462 1467